CA3201123A1 - Methodes de traitement de troubles psychiatriques par brexpiprazole chez des patients obeses - Google Patents

Methodes de traitement de troubles psychiatriques par brexpiprazole chez des patients obeses

Info

Publication number
CA3201123A1
CA3201123A1 CA3201123A CA3201123A CA3201123A1 CA 3201123 A1 CA3201123 A1 CA 3201123A1 CA 3201123 A CA3201123 A CA 3201123A CA 3201123 A CA3201123 A CA 3201123A CA 3201123 A1 CA3201123 A1 CA 3201123A1
Authority
CA
Canada
Prior art keywords
brexpiprazole
dose
days
day
cyp2d6
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3201123A
Other languages
English (en)
Inventor
Sundar Srinivasan
Christina Chow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lake O'hara LLC
Original Assignee
Lake O'hara LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/139,627 external-priority patent/US11229644B1/en
Priority claimed from US17/139,690 external-priority patent/US20220202810A1/en
Application filed by Lake O'hara LLC filed Critical Lake O'hara LLC
Publication of CA3201123A1 publication Critical patent/CA3201123A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente divulgation concerne des méthodes de démarrage d'un traitement par brexpiprazole chez des patients atteints de schizophrénie ou d'une dépression majeure. La présente divulgation concerne en outre des posologies modifiées pour les patients obèses et/ou pour les patients qui sont de mauvais métaboliseurs du CYP2D6. Dans des modes de réalisation, les posologies modifiées administrent une dose quotidienne doublée lors du démarrage du traitement.
CA3201123A 2020-12-31 2021-02-03 Methodes de traitement de troubles psychiatriques par brexpiprazole chez des patients obeses Pending CA3201123A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17/139,627 US11229644B1 (en) 2020-12-31 2020-12-31 Methods of treating psychiatric disorders in obese patients with brexpiprazole
US17/139,627 2020-12-31
US17/139,690 US20220202810A1 (en) 2020-12-31 2020-12-31 Methods of treating psychiatric disorders in obese patients with brexpiprazole
US17/139,690 2020-12-31
PCT/US2021/016329 WO2022146462A1 (fr) 2020-12-31 2021-02-03 Méthodes de traitement de troubles psychiatriques par brexpiprazole chez des patients obèses

Publications (1)

Publication Number Publication Date
CA3201123A1 true CA3201123A1 (fr) 2022-07-07

Family

ID=82259620

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3201123A Pending CA3201123A1 (fr) 2020-12-31 2021-02-03 Methodes de traitement de troubles psychiatriques par brexpiprazole chez des patients obeses

Country Status (5)

Country Link
EP (1) EP4271381A4 (fr)
JP (1) JP2024502431A (fr)
AU (1) AU2021412785A1 (fr)
CA (1) CA3201123A1 (fr)
WO (1) WO2022146462A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11229644B1 (en) 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
WO2023141634A2 (fr) * 2022-01-24 2023-07-27 Lake O'hara Llc Méthodes de traitement à base de brexpiprazole chez des patients obèses atteints de troubles psychiatriques

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0618879D0 (en) * 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
HUE043059T2 (hu) * 2013-02-27 2019-07-29 Mochida Pharm Co Ltd Új pirazolszármazék
CA2904387C (fr) * 2013-03-15 2021-12-07 Melinta Therapeutics, Inc. Procedes de traitement d'infections chez des patients atteints de surpoids et d'obesite utilisant d'antibiotiques
PL3426250T3 (pl) * 2017-05-16 2022-08-08 Bow River LLC Leczenie pacjenta lekiem będącym substratem CYP3A4 przeciwwskazanym do jednoczesnego podawania z silnym inhibitorem CYP3A4
CA3092335A1 (fr) * 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Strategie de dosage d'aripiprazole
US12357598B2 (en) * 2018-12-21 2025-07-15 The Regents Of The University Of California Treatment of neurodevelopmental disorders

Also Published As

Publication number Publication date
JP2024502431A (ja) 2024-01-19
WO2022146462A1 (fr) 2022-07-07
AU2021412785A1 (en) 2023-06-22
EP4271381A1 (fr) 2023-11-08
EP4271381A4 (fr) 2024-12-11

Similar Documents

Publication Publication Date Title
Horrigan et al. A phase 2 study of AMO-02 (Tideglusib) in congenital and childhood-onset myotonic dystrophy type 1 (DM1)
EP3716976B1 (fr) Procédés de traitement avec des médicaments à base de substrat du cyp3a4
JP2024180450A (ja) ５－ｈｔ２ｂアゴニストの形成を阻害するための製剤およびその使用方法
JP6193592B2 (ja) ピルフェニドン療法を施す方法
JP2021119189A (ja) ジストニアを治療するためのプリドピジンの使用
JP2023075247A (ja) ウィルソン病を治療するためのビスコリンテトラチオモリブデート
CN119072304A (zh) 用于治疗cns相关障碍的神经活性类固醇
US20230414606A1 (en) Methods of treating psychiatric disorders in obese patients with brexpiprazole
US20250057833A1 (en) Methods of treating psychiatric disorders in obese patients with brexpiprazole
WO2022146462A1 (fr) Méthodes de traitement de troubles psychiatriques par brexpiprazole chez des patients obèses
CN115397420A (zh) 阿立哌唑治疗的剂量起始方法
US20220202810A1 (en) Methods of treating psychiatric disorders in obese patients with brexpiprazole
US10799498B2 (en) Methods of treating depression
AU2018386182B2 (en) Methods for treating Gaucher disease
JP2026501567A (ja) Ｒ－ケタミンの投与方法
JP2024525424A (ja) 脳性麻痺によるジスキネジアの処置における使用のためのバルベナジン
CA3083663C (fr) Methodes de traitement de la maladie de gaucher
JP2026504721A (ja) 双極ｉ型障害及び統合失調症の治療のためのイロペリドンの投与レジメン
RU2781242C2 (ru) Способы лечения болезни гоше
CN119947712A (zh) 他西匹啶和cyp2d6抑制剂组合疗法
Pandya Antipsychotics: uses, actions and prescribing rationale
Pigeolet et al. PII‐55: Retrospective population pharmacokinetic analysis of levetiracetam in Westerner and Japanese adults

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241216

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241216

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241216

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250131

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250131

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250131

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250203

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250224

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250224

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250224

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250506

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251223

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251223